Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions

Cancer

Volumn 107, Issue 5, 2006, Pages 999-1007

  Lee, Bang Ning ^a   Follen, Michele ^a   Rodriquez, Graciela ^a   Shen, De Yu ^a   Malpica, Anais ^a   Shearer, William T ^b   Reuben, James M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cervical squamous intraepithelial lesions; Dendritic cells; Human papillomavirus; T cell proliferation

Indexed keywords

B7 ANTIGEN; BETA INTEGRIN; CD123 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 3 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; PRIORITY JOURNAL; SQUAMOUS CELL; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX SQUAMOUS INTRAEPITHELIAL LESION; VIRUS INFECTION; WART VIRUS;

ADULT; ANTIGEN PRESENTATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; T-LYMPHOCYTES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 33747887319     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22092     Document Type: Article

References (43)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
2. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-699.
3. Evander M, Edland K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995;171:1026-1030.
4. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
5. Scott M, Stites DR Moscicki AB. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol. 1999:6:751-755.
6. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;6:751-755.
7. Bontkes HJ, de Gruijl TD, Walboomers JMM, et al. Immune responses against human papillomavirus type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol. 1999;80:409-417.
8. Matsumoto K, Yasugi T, Oki A, et al. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. Cancer Lett. 2006;231:309-313.
9. Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol. 2005;99(3 Suppl 1):S251-261.
10. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005;174:7172-7178.
11. Lenz P, Lowy DR, Schiller JT. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol. 2005;35:1548-1556.
12. Lenz R Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol. 2003;106:231-237.
13. Yan M, Peng J, Jabbar IA, et al. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology. 2004;324:297-310.
14. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002;169:3242-3249.
15. Cheng WF, Lee CN, Su YN, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus- infected populations. Immunology. 2005;115:136-149.
16. Warrino DE, Olson WC, Kanpp WT, et al. Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human paillomavirus-16 E7 epitopes. Clin Cancer Res. 2004;10:3301-3308.
17. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology [see Comment]. JAMA. 2002;287:2114-2119.
18. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183-1186.
19. Zhang YQ, Joost van Neerven RJ, Van Gool SW, Coorevits L, de Boer M, Ceuppens JL. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Int Immunol. 1997;9:1095-1102.
20. Nimako M, Fiander AN, Wilkinson GWG, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 1997;57:4855-4861.
21. Nakagawa M, Stiles D, Farhat S, et al. Cytotoxic T lymphocyte response to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical epithelial neoplasia. J Infect Dis. 1997;175:927-931.
22. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer. 2003;103:519-524.
23. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59-65.
24. Gilliet M, Liu Y.-J. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol. 2002;63:1149-1155.
25. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol. 2004;35:1376-1384.
26. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
27. Nakagawa MSD, Patel S, Farhat S, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis. 2000;182:595-598.
28. Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Carrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens. 1993;41:65-71.
29. Cromme FV, Meijer CJ, Snijders PJ, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer. 1993;67:1372-1382.
30. Jimenez-Flores R, Mendez-Cruz R, Ojeda-Ortiz J, et al. High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology. 2006;117:220-228.
31. Spitkovsky D, Hehner SP Hofmann TG, Moller A, Schmitz ML. The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem. 2002;277:25576-25582.
32. Valdespino V, Gorodezky C, Ortiz V, et al. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol. 2005;96:92-102.
33. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 1999;59:1184-1187.
34. Schoell WMJ, Mirhashemi R, Liu B, et al. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. Gynecol Oncol. 1999;74:448-455.
35. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-698.
36. Chen QY, Bian ML, Chen ZH, Liu J. Detection of integration status of human papillomavirus 16 in cervical precancerous lesions. Zhonghua Yi Xue Za Zhi. 2005;85:400-404.
37. Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol. 2004;34:3525-3533.
38. Lee B-N, Follen M, Shen D-Y, et al. Depressed type 1 cytokine synthesis by superantigen-activated CD4+ T cells of women with human papillomavirus- related high-grade squamous intraepithelial lesions. Clin Diagn Lab Immunol. 2004;11:239-244.
39. Neumann J, Eis-Hubinger AM, Koch N. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol. 2003;171:3075-3083.
40. Beck S, Schreiber H, Rowley D. Role of TGF-beta in immuneevasion of cancer. Microsc Res Tech. 2001;52:387-395.
41. Guinet E, Yoshida K, Nouri-Shirazi M. Nicotinic environment affects the differentiation and functional maturation of monocytes derived dendritic cells (DCs). Immunol Lett. 2004;95:45-55.
42. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions [see Comment]. Immunology. 2003;109:365-373.
43. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol. 2005;175:2684-2691.